Latest
Europeans OK expanded use of Amgen’s Blincyto
The European Commission approved an expanded use for Amgen’s leukemia therapy Blincyto in treating pediatric patients Aug. 29. Based on results from a study of 93 pediatric patients, the approval allows its use in patients a year old or older with a particular type of relapsed or refractory acute lymphoblastic leukemia. “Historically, children with relapsed Read More →
